Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bortezomib
Drug ID BADD_D00284
Description Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma.[A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib.[L14180] However, multiple mechanisms may be involved in the anticancer activity of bortezomib.[A204083] Bortezomib was first synthesized in 1995.[A204083] In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE.[A204146] Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumours.[A214307]
Indications and Usage Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma.[L14177]
Marketing Status approved; investigational
ATC Code L01XG01
DrugBank ID DB00188
KEGG ID D03150
MeSH ID D000069286
PubChem ID 387447
TTD Drug ID D0SH3I
NDC Product Code 62158-0011; 65129-1264; 0409-1703; 70710-1411; 51817-586; 68001-541; 14096-140; 0143-9098; 67184-0530; 71288-118; 72205-183; 63323-821; 12502-5268; 42385-716; 55111-922; 63323-721; 68001-534; 48957-0018; 10019-991; 70225-1102; 50742-484; 70511-161; 47848-031; 54893-0011; 66529-0006; 76055-0027; 82920-006; 0409-1704; 70771-1708; 72266-243; 72266-244; 54245-7004; 62207-972; 67184-0026; 60505-6050; 70511-162; 25021-244; 68001-540; 42973-140; 55150-337; 63020-049; 0409-1700; 70860-225; 62756-982; 68554-0051; 78848-009
UNII 69G8BD63PP
Synonyms Bortezomib | LDP-341 | LDP 341 | LDP341 | PS 341 | 341, PS | PS-341 | PS341 | Velcade
Chemical Information
Molecular Formula C19H25BN4O4
CAS Registry Number 179324-69-7
SMILES B(C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Platelet aggregation increased13.01.04.010--Not Available
Platelet count decreased13.01.04.001--
Platelet disorder01.08.03.001--Not Available
Pleural effusion22.05.02.0020.000918%
Pleurisy22.05.01.001--Not Available
Pneumonia22.07.01.003; 11.01.09.003--Not Available
Pneumonia aspiration22.07.01.015; 11.01.09.019--Not Available
Pneumonitis22.01.01.0060.000616%
Pneumothorax22.05.02.003--
Pollakiuria20.02.02.007--
Polyneuropathy17.09.03.0120.001948%Not Available
Poor peripheral circulation24.04.03.013--Not Available
Portal vein thrombosis24.01.03.003; 09.01.06.007--
Post herpetic neuralgia17.02.07.014; 11.07.01.010--Not Available
Presyncope02.11.04.013; 24.06.02.010; 17.02.05.009--
Proctalgia07.03.02.001--
Progressive multifocal leukoencephalopathy17.16.02.002; 11.05.05.001--Not Available
Prostatitis21.09.01.001--Not Available
Proteinuria20.02.01.0110.000414%
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002--Not Available
Pulmonary alveolar haemorrhage24.07.01.015; 22.01.02.0050.000280%Not Available
Pulmonary embolism24.01.06.001; 22.06.02.001--Not Available
Pulmonary fibrosis22.01.02.0060.000280%
Pulmonary hypertension22.06.01.001; 24.08.03.002--
Pulmonary oedema22.01.03.003; 02.05.02.003--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.0030.000112%
Pyrexia08.05.02.0030.007331%
Radiation injury12.05.02.003--Not Available
Radiculopathy17.10.01.0050.000224%
The 15th Page    First    Pre   15 16 17 18 19    Next   Last    Total 26 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene